Similar articles

• Comment on: The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis.

  Akkerman OW, Alffenaar JWC. Akkerman OW, et al. J Antimicrob Chemother. 2019 Mar 1;74(3):834. doi: 10.1093/jac/dky490. J Antimicrob Chemother. 2019. PMID: 30508093 No abstract available.
• Clinical use of rifabutin, a rifamycin-class antibiotic, for the treatment of tuberculosis (A supplement to the 2008 revision of "Standards for tuberculosis care").

  Treatment Committee of the Japanese Society for Tuberculosis; International Exchanging Committee of the Japanese Society for Tuberculosis. Treatment Committee of the Japanese Society for Tuberculosis, et al. Kekkaku. 2011 Jan;86(1):43. Kekkaku. 2011. PMID: 21401006 No abstract available.
• Rifampin.

  [No authors listed] [No authors listed] Tuberculosis (Edinb). 2008 Mar;88(2):151-4. doi: 10.1016/S1472-9792(08)70024-6. Tuberculosis (Edinb). 2008. PMID: 18486058 Review. No abstract available.
• Rifalazil.

  [No authors listed] [No authors listed] Tuberculosis (Edinb). 2008 Mar;88(2):148-50. doi: 10.1016/S1472-9792(08)70023-4. Tuberculosis (Edinb). 2008. PMID: 18486057 Review. No abstract available.
• Cycloserine.

  [No authors listed] [No authors listed] Tuberculosis (Edinb). 2008 Mar;88(2):100-1. doi: 10.1016/S1472-9792(08)70007-6. Tuberculosis (Edinb). 2008. PMID: 18486041 Review. No abstract available.